Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy.
Grande E, Alonso-Gordoa T, Reig O, Esteban E, Castellano D, Garcia-Del-Muro X, Mendez MJ, García-Donas J, González Rodríguez M, Arranz-Arija JA, Lopez-Criado P, Molina-Cerrillo J, Mellado B, Alvarez-Fernandez C, De Velasco G, Cuéllar-Rivas MA, Rodríguez-Alonso RM, Rodríguez-Moreno JF, Suarez-Rodriguez C.
Grande E, et al. Among authors: rodriguez alonso rm.
ESMO Open. 2022 Apr;7(2):100463. doi: 10.1016/j.esmoop.2022.100463. Epub 2022 Apr 8.
ESMO Open. 2022.
PMID: 35405437
Free PMC article.
Clinical Trial.